MK-0677 IN GROWTH HORMONE DEFICIENT CHILDREN

目前，重组人生长激素是唯一的治疗方法， 为GH缺乏症儿童提供。 这种疗法导致 在治疗第一年中生长速度急剧加快 然后通常在随后的几年治疗中缓慢下降。 用rhGH治疗是肠胃外的且昂贵的， GH释放的正常脉冲模式。 MK-0677是一种口服活性物质， 生长激素释放肽的模拟物， 脉冲式GH分泌。本研究旨在提供剂量- 为后续试验提供范围信息，并评估安全性， MK-0677对生长激素缺乏儿童的疗效 既往接受过重组GH治疗的患者。 这些假设是 该处理将导致平均生长的剂量依赖性差异 治疗6个月后，MK-0677将安全且良好 容忍。 目的是评估疗效和安全性， 获得与重组GH治疗的比较数据。

Currently, recombinant human growth hormone constitutes the only therapy available to children with GH deficiency. This therapy results in a dramatic acceleratin of growth velocity during the first year of therapy then generally slowly declines over subsequent years of treatment. Therapy with rhGH is parenteral and expensive and does not mimic the normal pulsatile pattern of GH release. MK-0677 is an orally active mimetic of the growth hormone-releasing peptides which stimulates pulsatile secretion of GH. This study is intended to provide dose- ranging information for subsequent trials and to assess the safety and efficacy of administering MK-0677 to growth hormone deficient children who have been previously treated with recombinant GH. The hyptheses are that treatment will result in dose-dependent differences in mean growth velocity after 6 months of treatment and MK-0677 will be safe and well tolerated. The objectives are to assess the efficacy and safety and to obtain comparative data to treatment with recombinant GH.